COVID-19 mRNA Vaccine, Bivalent (Aimbio)

N/A

Report date: 2026/05/13 09:17:09

Base Information

Drug NameCOVID-19 mRNA Vaccine, Bivalent (Aimbio)
Drug Alias NameLVRNA021
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPakistanMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAim Vaccine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLiveRNA Therapeutics IncAim Vaccine Co LtdNingbo Rongan Biological Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A